After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Learn about Leqembi, Saudi Arabia's first approved treatment for Alzheimer’s disease, marking a major advancement in ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

In a historic first, Saudi Arabia has approved Leqembi (lecanemab)—a breakthrough drug that targets early-stage ...

Because Leqembi is a Part B drug, not a more common Part D drug, many Medicare patients will owe 20 percent of the cost out-of-pocket. That adds up to more than $5,000 annually.

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to ...

Eisai spokeswoman Libby Holman said prescriptions for Leqembi have been written, and that the company expects patients to begin receiving the drug soon. It will cost about $26,500 for a year of ...

We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize ...

LEQEMBI is the only FDA- approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option. TOKYO and CAMBRIDGE, Mass., Jan ...